Phase 2a study was initiated by Handok Pharmaceuticals in Q1 2021 in patients with Biliary Tract Cancers (cholangiocarcinoma). Enrollment in the first part of the study has been completed and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback